Premium
Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: Correlation with androgen independence
Author(s) -
Shah Rajal B.,
Ghosh Debashis,
Elder James T.
Publication year - 2006
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20460
Subject(s) - prostate cancer , tissue microarray , prostate , medicine , androgen receptor , androgen , oncology , cancer , tumor progression , epidermal growth factor , epidermal growth factor receptor , erbb , hormone , cancer research , endocrinology , receptor
BACKGROUND The role of the epidermal growth factor receptor (ErbB1) in the progression of prostate cancer is incompletely understood. METHODS Tissue microarrays from hormone‐naive and advanced androgen‐independent tumors were used to investigate the role of ErbB1 in prostate cancer progression. RESULTS ErbB1 expression in tumor tissues was strongly associated with hormone‐refractory status (odds ratio = 6.67, 95% CI = (2.6, 17.4), P = 0.0001). However, ErbB1 overexpression was not a statistically significant covariate in a multivariate proportional hazards model for biochemical failure of hormone‐naïve prostate cancer. Moreover, ErbB1 overexpression was not associated with tumor differentiation ( P = 0.44), positive margins ( P = 0.53), seminal vesicle invasion ( P = 0.69), extraprostatic extension ( P = 0.10), or preoperative PSA ( P = 0.18) in the hormone‐naïve group. CONCLUSIONS These findings are consistent with a model in which ErbB1 expression increases during the development of the androgen‐independent state, and suggest that drugs targeted toward ErbB signaling could be of therapeutic relevance in the management of advanced prostatic carcinoma. Prostate 66: 1437–1444, 2006. © 2006 Wiley‐Liss, Inc.